Blog Coverage Celgene’s Multiple Sclerosis Drug Reported Positive Phase-III Results

Upcoming AWS Coverage on BioMarin Pharmaceutical Post-Earnings Results

LONDON, UK / ACCESSWIRE / February 21, 2017 / Active Wall St. blog coverage looks at the headline from Celgene Corp. (NASDAQ: CELG) as the Company announced on February 17, 2017, that it took a major step forward toward becoming an important player in the multiple sclerosis treatment market after the Company announced positive results from its phase-III SUNBEAM trial, evaluating the efficacy and safety of its oral drug ozanimod in patients with relapsing multiple sclerosis (RMS). Register with us now for your free membership and blog access at:

http://www.activewallst.com/register/

One of Celgene’s competitors within the Biotechnology space, BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), reported on February 07, 2017, that Jean-Jacques Bienaimé, the Company’s Chairman and Chief Executive Officer, will host a conference call and webcast on Thursday, February 23, at 4:30 p.m. ET to discuss Q4 and full year 2016 financial results and provide a general business update. AWS will be initiating a research report on BioMarin Pharma in the coming days.

Today, AWS is promoting its blog coverage on CELG; touching on BMRN. Get all of our free blog coverage and more by clicking on the links below:

http://www.activewallst.com/register/

The SUNBEAM Trial

SUNBEAM is a phase-III multicenter, randomized, double-blind, double-dummy, active-controlled study assessing the efficacy, safety, and tolerability of two orally administered doses of ozanimod (0.5 mg and 1 mg) against weekly intramuscular interferon beta-1a (Avonex®) over a minimum of a 12-month treatment period. The randomized phase-III trial enrolled 1,346 RMS patients across 152 sites in 20 countries.

Celgene noted that the top-line results revealed that both the ozanimod 1 mg and 0.5 mg treatment arms demonstrated statistically significant and clinically meaningful improvements compared to Biogen’s Avonex® for the primary endpoint of annualized relapse rate (ARR) in RMS patients. Ozanimod also came top in the secondary endpoints of the number of gadolinium-enhancing MRI lesions and the number of new or enlarging T2 MRI lesions at month 12. The Company stated that as per its Special Protocol Assessment (SPA) with the US Food and Drug Administration (FDA), a pre-specified analysis on the time to onset of disability progression will be conducted using pooled results from both the SUNBEAM and RADIANCE phase-III trials.

Celgene noted that ozanimod’s overall safety and tolerability profile was consistent with results from previously reported phase-II RMS (RADIANCE) and phase-II ulcerative colitis (TOUCHSTONE) trials.

“People living with multiple sclerosis need additional therapies and we are pleased that oral ozanimod showed meaningful improvements across primary and measured secondary endpoints in this study,” said Scott Smith, President of Celgene Inflammation and Immunology. “We look forward to data from the confirmatory phase-III RADIANCE trial in the second quarter as we advance toward planned regulatory submissions by year-end.”

About Ozanimod

Ozanimod is a novel, oral, selective, sphingosine 1-phosphate 1 (S1PR1), and 5 (S1PR5) receptor modulator in development for immune-inflammatory indications including relapsing multiple sclerosis, ulcerative colitis and Crohn’s disease. Selective binding with S1PR1 receptors is believed to inhibit a specific sub set of activated lymphocytes from migrating to sites of inflammation. The result is a reduction of circulating T and B lymphocytes that leads to anti-inflammatory activity. Importantly, immune surveillance is maintained. Ozanimod was acquired by Celgene under its $7 billion purchase of Receptos in 2015.

Selective binding with S1PR5 receptors is believed to activate specific cells within the CNS. This has the potential to enhance remyelination and prevent synaptic defects. Ultimately, neurological damage may be prevented.

Stock Performance

At the closing bell, on Friday, February 17, 2017, following the announcement, Celgene’s stock climbed 2.11%, ending the trading session at $121.16. A total volume of 4.85 million shares were traded at the end of the day, which was higher than the 3-month average volume of 4.28 million shares. In the last month and previous six months, shares of the Company have advanced 6.64% and 8.05%, respectively. Moreover, the stock gained 4.67% since the start of the year. Shares of the company have a PE ratio of 48.74 and have a market cap of $94.13 billion.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com
Phone number: 1-858-257-3144
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 455608